key: cord-0797132-bnyty734 authors: Kurtzberg, Joanne title: The view for cord blood is “cup half full” not “cup half empty” date: 2020-07-03 journal: Stem Cells Transl Med DOI: 10.1002/sctm.20-0260 sha: 2047865ecd468c1ce5436771382a0ee9edef0d6a doc_id: 797132 cord_uid: bnyty734 nan In this issue of the journal, Kindwall-Keller and Ballen present a targeted overview of the advantages, disadvantages, and milestones of cord blood transplantation over the past 30 years. 1 First they highlight the advantages of cord blood as a source of donor cells for hematopoietic transplantation, including off the shelf availability, increased tolerance for HLA mismatching, lower incidence of acute and chronic GvHD, lower risk of infectious disease transmission, and improved protection against leukemic relapse in high risk patient populations. They also make several important points about the limitations of cord blood in transplantation, highlighting slower engraftment, delayed immune reconstitution, and cost amongst others. Overall, the report is somewhat pessimistic about the overall outlook of this novel graft source. More than 4 decades ago, Hal Broxmeyer showed that cord blood (CB), the baby's blood left over in the placenta after birth and usually discarded as medical waste, was enriched for hematopoietic stem and progenitor cells (HSCs). 2 He further demonstrated that CB cells had a higher proliferative capacity and higher ratios of stem to progenitor cells compared with adult bone marrow (BM) confirming the old saying that "younger is better." Broxmeyer led a group of investigators in NYC to develop techniques to collect and cryopreserve CB with the goal of performing a transplant in which CB was substituted for BM as the source of HSCs. The 1993-1996, were reported by my group in 1996. 5 This was followed by additional reports of UCBT outcomes, all demonstrating that CB could be cryopreserved and banked, that CB conferred durable myeloid and lymphoid engraftment (albeit at a slower rate, increasing treatment-related mortality than other sources of HSCs), and that CB was transplantable without full HLA matching without increasing the incidence of GvHD, thereby providing donors for patients unable to identify donors in their families or the adult unrelated registries. [6] [7] [8] Over the subsequent decade, hundreds of cord blood banks, both public and private, were established worldwide. Internationally, an inventory approaching 800 000 units has been accrued to public cord blood banks. In the US, federally sponsored legislation, the C.W. Bill 12 CB is also an ideal graft source for newborns and infants where cell dose is relatively higher and engraftment is rapid. In addition, because CB is essentially an "off-the-shelf" product, it is readily available as a donor source for infants diagnosed with congenital leukodystrophies or immune deficiency syndromes requiring transplantation in the first 1-2 months of life. With more and more of these diseases being diagnosed through newborn screening, the need for CB as the donor source for transplantation will increase. Furthermore, for some genetic diseases, collection of autologous cord blood to be used as the source of HSCs for transfection provides an ideal, non-invasive source of cells for this technology. In sickle cell disease, where maintenance of expression of the gamma gene is a novel approach to gene therapy, cord blood, where the gamma gene is biologically still "on" is the ideal source of HSCs for this approach. The ability to identify a fully matched donor for a patient in Program's Be the Match Registry and despite more than 32 million volunteer donors worldwide, full matching is becoming more and more challenging; therefore, a readily available source of donor cells that can be used without full matching but still capable of engrafting, causing minimal GvHD, and controlling leukemic relapse is highly desirable. Over the past 3-5 years, the use of haplo-identical related donors has emerged as a potential solution to this problem, but haplo transplants have increased relapse rates in some patients with blood cancers and increased rejection rates in some patients with genetic diseases, so haplo is not the perfect solution either. Finally, CB banks have developed unique expertise in GMP manufacturing of cellular products. They have created infrastructure to recruit donors, procure CB and birthing tissues, determine donor eligibility, test, process, cryopreserve, ship and thaw qualified CB units for transplantation. In addition, they have the expertise and regulatory bandwidth to procure, harvest and store birthing tissues which can be utilized to manufacture cell therapies for use in regenerative medicine. Highly effective immunotherapies including allogeneic CAR-NK and cytotoxic T-cells (CTLs) have been manufactured from cord blood and are in development for commercialization. 13, 14 Derivatives of cord blood CD14 monocytes are in clinical trials for treatment of hypoxic and demyelinating diseases [15] [16] [17] [18] and cord blood is being investigated as a therapy for children with autism spectrum disorder, a severely disabling disease with increasing prevalence in our society. 19, 20 Finally cord and placental tissues are robust sources of mesenchymal stromal cells which are undergoing testing in many diseases as immune modulators and suppressors of pro-inflammatory states, 21 including as a treatment for complications of COVID- 19. 22 So I'm not giving up on cord blood and products from related birthing tissues. The CB industry was the first to enter the regulated cell therapy environment, but its experience and progress to date can be leveraged for the development of many promising and exciting therapies to come. Umbilical cord blood: The promise and the uncertainty Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients Outcomes among 562 recipients of placental-blood transplants from unrelated donors Cord blood transplantation study (COBLT): cord blood bank standard operating procedures Results of the Cord Blood Transplantation Study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies Optimizing donor selection for public cord blood banking: influence of maternal infant and collection characteristics on cord blood unit quality Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy One-unit versus two-unit cord-blood transplantation for hematologic cancers Cord-blood transplantation in patients with minimal residual disease Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood Differences in quality between privately and publicly banked umbilical cord blood units: A pilot study of autologous cord blood infusion in children with acquired neurological disorders Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: A randomized, placebo-controlled trial Human umbilical cord blood monocytes, but not adult blood monocytes, rescue brain cells from hypoxic-ischemic injury: Mechanistic and therapeutic implications Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: Results of a single center phase I open label trial A phase II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for treatment of children with autism spectrum disorder Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome